A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

NCT07279597 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Muscle-invasive Bladder Urothelial Carcinoma

Interventions

DRUG: RC48-ADC + Toripalimab

Sponsor

Tongji Hospital